Kate Rawson
Senior Editor at Prevision Policy
Drug regulation/health policy journalist, downhill skier, cyclist, Mom to two, school choice supporter, library lover, Baltimore believer. Tweets are all me.
Articles
-
1 month ago |
insights.citeline.com | Kate Rawson
Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum? Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER. Before resigning as CBER director, Peter Marks said he thought the Trump Administration would continue supporting rare disease drug development. (Shutterstock)
-
2 months ago |
insights.citeline.com | Kate Rawson
Device-Like System Proposed For Low-Risk Human Cell Therapies, Tissue-Based Products At US FDA A risk-based approach to human cell therapies and tissue-based products could incentivize development and prevent bad actors from taking advantage of the current FDA system. The FDA wants to revamp its current regulatory framework for human cell and tissue-based therapies. (Shutterstock)
-
Dec 18, 2024 |
insights.citeline.com | Kate Rawson
Gene Therapy Follow-Up: Balance Data Needs And Patient Burden, Bluebird Bio Exec SaysHimal Thakur said the required long-term safety study can replicate a clinical trial, which is not the intent. The FDA often requires 15 years of postmarket follow-up for approved gene therapies. (Shutterstock)
-
Dec 9, 2024 |
insights.citeline.com | Kate Rawson
Flying Blind: Learning to Live Without Physician Prescribing Data01 Jan 2007 • By Kate RawsonPhysicians aren't happy about the prescribing information companies use to help develop sales and marketing activities, and they're doing something about it. Policies adopted by medical professionals--and legislation moving at the state level--threaten to cut off marketers' access to information about who prescribes their products. Pharma companies better prepare to adapt to new ways of tracking sales.
-
Dec 9, 2024 |
insights.citeline.com | Kate Rawson
Live Free or Die? New Hampshire Court Lifts Ban on Physician Prescribing Data 01 May 2007 • By Kate RawsonPharmaceutical sales and marketing teams will have a much easier time selling their products in one US state-and may have avoided major restrictions in others across the country-after a New Hampshire law banning the use of physician prescribing data for commercial use was struck down in state court.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 523
- Tweets
- 1K
- DMs Open
- No
Looking forward to moderating at @CancerResrch’s Public Meeting “The Future of Diagnostic Tests: New Data & Modern Policy” Thursday, Feb. 1st, 2024 from 10:00AM - 2:30PM ET. Click to register here: https://t.co/ocmQe3Xh6s #AIOncology #FriendsDx #HRDFriends
RT @NateSilver538: Telling a stranger how often you did or didn't get COVID is approximately as interesting a conversation as telling a str…
After two years waiting for @US_FDA to figure out #audioissues during #VRBAC meetings, I can now easily hum along to each piece of hold music.
